President and Chief Executive Officer
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calitheraâ€™s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in- class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the bodyâ€™s cancer-fighting immune cells, known as cytotoxic T -cells. Calithera is headquartered in South San Francisco, California.
I have served as President, Chief Executive Officer and as a member of the board of directors at Calithera Biosciences since I co-founded the company in March 2010. Prior to Calithera, I co- founded Proteolix, Inc. in 2003 and served as Chief Scientific Officer and later as Chief Executive Officer in the company, prior to its acquisition by Onyx Pharmaceuticals, Inc. in 2009. I led the team that discovered the proteasome inhibitor carfilzomib (marketed as Kyprolis) and conducted the Phase 2 clinical trials that led to the accelerated approval of Kyprolis for the treatment of refractory multiple myeloma in 2012. Prior to founding Proteolix, I held various senior scientific and management positions at Rigel Pharmaceuticals, Inc., Praecis Pharmaceuticals Inc., and Merck & Co. I currently serve as a member of the board of directors of Geron Corporation, a biopharmaceutical company. I also serve as the Chairman of BayBio, Northern California’s Life Science Association. I received a B.S. degree in Biology from Smith College, a Ph.D. degree in Molecular Biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University.